NCT03195673 (TZ-CAS) is a Phase 2 clinical trial of Terazosin in Carotid Artery Stenosis, sponsored by Capital Medical University.

Who is sponsoring NCT03195673?

NCT03195673 is sponsored by Capital Medical University.

What drugs are being tested in NCT03195673?

Interventions in NCT03195673: Terazosin, Carotid artery stenting.

What condition does NCT03195673 study?

NCT03195673 studies Carotid Artery Stenosis.

Is NCT03195673 still recruiting?

NCT03195673 is currently status unknown. Last updated 11 December 2018.

Last reviewed 2018-12-11 · How we verify

NCT03195673: TZ-CAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

Status unknown Phase 2 Last updated 11 December 2018

What this trial tests

Phase 2 trial testing Terazosin in Carotid Artery Stenosis in 160 participants. Status unknown.

Timeline

2 March 2018

Primary endpoint
15 November 2019

15 December 2019

Quick facts

Lead sponsor	Capital Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	160
Start date	2 March 2018
Primary completion	15 November 2019
Estimated completion	15 December 2019
Sites	2 locations across China

Drugs / interventions tested

Terazosin (TERAZOSIN) — full drug profile →
Carotid artery stenting

Conditions studied

Carotid Artery Stenosis — all drugs for Carotid Artery Stenosis →

Sponsor

Capital Medical University

Who can join

Adults 18 to 80, any sex, with Carotid Artery Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and efficacy of low dosage of Terazosin in Carotid Artery Stenting

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Terazosin

Trials testing the same drug.

NCT06966804 — Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms · Phase 3 · recruiting
NCT04551040 — Target Engagement of Terazosin in Healthy Adults · Phase 1 · active not recruiting
NCT04386317 — Terazosin Effect on Cardiac Changes in Early Parkinson's Disease · Phase 2 · active not recruiting

Other recruiting trials for Carotid Artery Stenosis

Currently open trials in the same condition.

NCT07370246 — CAS for Stenosis With High-risk Features for CEA · NA · recruiting
NCT07247864 — Balloon Guide Catheter Combined With Filter Protection for Carotid Artery Stenting · NA · recruiting
NCT06924593 — Study on the Trans-Carotid Artery Occlusion Shunt System · NA · recruiting
NCT07034157 — A Real-World Study on Ultrasound-Based Screening and Integrated Therapeutic Strategies for Patients With Concomitant Cor · recruiting
NCT06936176 — Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial) · NA · recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03195673 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 11 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03195673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing